Kisspeptin-10 vs Mod-GRF(1-29)
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Kisspeptin-10
Kisspeptin-10 is the biologically active 10-amino acid C-terminal fragment of kisspeptin, a neuropeptide that acts as the master regulator of the hypothalamic-pituitary-gonadal (HPG) axis. By activating KISS1R (GPR54) in the hypothalamus, it triggers pulsatile GnRH release, which drives LH, FSH, and downstream testosterone and estrogen production. It is the upstream signal that 'turns on' the reproductive axis — with research applications spanning fertility, hypogonadism, post-cycle therapy support, and age-related hormonal decline.
Full profileMod-GRF(1-29)
Mod-GRF(1-29) is a stabilized analog of growth hormone-releasing hormone (GHRH) that spans residues 1–29 of the native peptide. Unlike CJC-1295 (which includes a Drug Affinity Complex for multi-day half-life), Mod-GRF(1-29) has a short ~30-minute active window — mimicking the natural GHRH pulse pattern. It is the preferred GHRH component for precise, pulsatile GH protocols when combined with a GHRP.
Full profile| Kisspeptin-10 | Mod-GRF(1-29) | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | KP-10, Metastin(112-121), KISS1R agonist | Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog |
| Evidence | FDA-approved | Research-stage |
| Dosing range | 50mcg–250mcg mcg, 1–2x daily (pulsatile administration is important — avoid continuous infusion) | 100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking) |
| Administration | Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses) | Subcutaneous injection, Intramuscular injection |
| Key side effects | Generally well-tolerated in clinical trials, Nausea (mild, uncommon), Potential for over-stimulation of the HPG axis at high doses (rarely significant), Theoretical desensitization with continuous (non-pulsatile) dosing | Water retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: Kisspeptin-10 is fda-approved, while Mod-GRF(1-29) is research-stage.
- Administration: Kisspeptin-10 — Subcutaneous injection, Intranasal, Intravenous (clinical studies — produces most reliable LH pulses); Mod-GRF(1-29) — Subcutaneous injection, Intramuscular injection.
- Frequency: Kisspeptin-10 is typically 1–2x daily (pulsatile administration is important — avoid continuous infusion); Mod-GRF(1-29) is 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking).
- Research depth: this profile cites 3 sources for Kisspeptin-10 vs 2 for Mod-GRF(1-29).
How each works
Kisspeptin-10
Kisspeptin neurons in the arcuate nucleus form the pulse generator for GnRH secretion — without kisspeptin signaling, reproductive function ceases. Human clinical trials confirm that IV kisspeptin-10 produces rapid, dose-dependent LH pulses in both males and females, restoring hormonal function in hypogonadotropic hypogonadism. Kisspeptin-54 (the longer form) has been studied in human fertility treatments with successful outcomes. Unlike direct LH/FSH administration, kisspeptin works upstream at the hypothalamus, preserving the natural pulsatile release pattern and avoiding receptor desensitization associated with continuous GnRH agonists.
Mod-GRF(1-29)
Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.